Intervention: Molnupiravir

MOVe-NOW

Argentina Brazil Bulgaria Colombia Finland France Georgia Germany Italy Japan Mexico New Zealand Peru Philippines Poland Puerto Rico Romania Spain Taiwan Thailand Ukraine United Kingdom United States of America
|
2024-2031
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

Paraskevis

Greece
|
2022-2022
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Del Borgo

Italy
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Mikulska

Italy
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Colaneri 2

Italy
|
2021-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Patel

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab

De Vito

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

Rinaldi

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Drysdale 3

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab

Rotundo

Italy
|
2022-2023
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Villamarin

Spain
|
2022-2022
  • Adults (18-64 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir